Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;14(5):407-417.
doi: 10.1080/17474086.2021.1938533. Epub 2021 Jun 15.

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia

Tamer A Othman  1 , Matthew E Tenold  1 , Benjamin N Moskoff  2 , Tali Azenkot  3 , Brian A Jonas  1
Affiliations
Review

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia

Tamer A Othman et al. Expert Rev Hematol. 2021 May.

Abstract

Introduction: Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, current use, and future directions.

Areas covered: This review covers the clinical development of venetoclax-based combinations for the management of AML, and their current and future use. A search of PubMed and ashpublications.org using the keywords 'venetoclax', 'AML', and 'hypomethylating agents' as the search terms was undertaken to identify the most pertinent publications.

Expert opinion: While venetoclax-based combinations have shown excellent responses and improved survival in patients with untreated AML, further studies are required to understand how to expand on their frontline use, manage patients who fail venetoclax-based combinations, and their true efficacy in the relapsed/refractory setting. Management of AML with venetoclax-based combinations is expected to evolve over the next few years.

Keywords: Acute myeloid leukemia; aml; azacitidine; cytarabine; decitabine; hma; hypomethylating agent; ldac; venetoclax.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1:
Figure 1:
HMA-VEN demonstrates synergistic activity against leukemic stem cells by inhibiting amino acid uptake and disrupting the tricarboxylic acid (TCA) cycle via inhibition of electron transport chain complex II, ultimately leading to cell death. Amino acids are represented in red circles.
See this image and copyright information in PMC

References

    1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 373(12), 1136–1152 (2015). - PubMed
    1. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev 36 70–87 (2019). - PubMed
    1. Davis JR, Benjamin DJ, Jonas BA. New and emerging therapies for acute myeloid leukaemia. J Investig Med 66(8), 1088–1095 (2018). - PMC - PubMed
    1. Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3), 453–474 (2010). - PubMed
    1. Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33(12), 2795–2804 (2019). - PubMed

Publication types

MeSH terms